Supernus Pharmaceuticals (SUPN) EBITDA Margin Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) EBITDA Margin Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.67 Bn | 2.30 Bn | 185.39 Mn | -1,349.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,349.00 |
| Dec 31, 2025 | -2,238.00 |
| Sep 30, 2025 | -3,049.00 |
| Jun 30, 2025 | 67.00 |
| Mar 31, 2025 | -814.00 |
| Dec 31, 2024 | 846.00 |
| Sep 30, 2024 | 129.00 |
| Jun 30, 2024 | -1,073.00 |
| Mar 31, 2024 | -1,229.00 |
| Dec 31, 2023 | -3,056.00 |
| Sep 30, 2023 | -3,090.00 |
| Mar 31, 2023 | -2,718.00 |
| Dec 31, 2022 | -2,012.00 |
| Sep 30, 2022 | -3,976.00 |
| Jun 30, 2022 | -3,402.00 |
| Mar 31, 2022 | -2,846.00 |
| Dec 31, 2021 | -3,054.00 |
| Sep 30, 2021 | -1,442.00 |
| Jun 30, 2021 | -1,175.00 |
| Mar 31, 2021 | -2,462.00 |